# Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

> **NCT05287308** · NA · NOT_YET_RECRUITING · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 500 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** doxorubicin
- **DRUG:** epirubicin
- **DRUG:** pirarubicin
- **DRUG:** cyclophosphamide
- **DRUG:** albumin-bound paclitaxel
- **DRUG:** paclitaxel
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT05287308
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-03
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05287308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05287308, "Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05287308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*